Key Highlights

  • Shares were down 15.70% to USD 3.06 in pre-market trading on November 3, 2026.
  • No company announcement dated November 2 or November 3, 2026 was identified.
  • Second-quarter 2026 Revenue was USD 11.4 million, up 1.7% from a year earlier.
  • Gross Margin reached 86.8% in the quarter, with cash of USD 46.3 million at June 30, 2026.
  • Full-year 2026 revenue guidance of USD 54 million to USD 57 million was maintained.

What is behind the pre-market drop (down USD 0.5699, 15.70%)

TriSalus Life Sciences (NASDAQ:TLSI) was down 15.70% to USD 3.06 in pre-market trading on November 3, 2026, measured against the Monday November 2, 2026 close. A search of company releases and regulatory filings dated October 30 to November 3, 2026 did not turn up a specific announcement. Without a stated trigger, the decline looks like a reaction to general sentiment, thin pre-market Liquidity or positioning ahead of the company's next Earnings report, though none of those can be confirmed.

The most recent results on record

The latest financial update came in an earnings release dated August 6, 2026, for the quarter ended June 30, 2026. Revenue was USD 11.4 million, up 1.7% from USD 11.2 million in the second quarter of 2025. Gross margin improved to 86.8% from 83.9%.

The net loss was USD 9.2 million, or USD 0.16 per share. Management said it expected growth to build in the second half of 2026 as its expanded sales organization matures. A third-quarter results date was not identified in the sources reviewed.

Business background and recent updates

TriSalus is a commercial-stage oncology company focused on delivering therapies to liver and pancreatic tumors. Its TriNav infusion system uses a pressure-generating catheter in a method the company calls pressure-enabled drug delivery.

In the August release, the company said a federal reimbursement code had been established to cover procedures using a pressure-generating catheter in physician office-based lab settings, with the rate still being finalized. It also said it had submitted data from its PEDIR study, a multi-center randomized trial at Massachusetts General Hospital, for publication.

Balance sheet and risks

Cash and equivalents stood at USD 46.3 million at June 30, 2026, against long-term Debt of USD 33.1 million. The company flagged covenant compliance and revenue requirements under its Credit Facility as risks.

There is also a gap between recent trading and the target. Second-quarter growth of 1.7% compares with full-year guidance implying 19 to 26% growth over 2025, so the second half carries the weight. Shares trading near USD 3 can swing widely on small volume, so Volatility and Liquidity Risk are real.

What to watch next

The next catalyst is likely the third-quarter earnings report and call, where investors will look for evidence that revenue is accelerating toward the guided range. Any update to the reimbursement rate for office-based procedures would also be closely read.